Cellectis (CLLS) Cut to “Hold” at ValuEngine
ValuEngine downgraded shares of Cellectis (NASDAQ:CLLS) from a buy rating to a hold rating in a research note published on Friday.
CLLS has been the topic of several other research reports. BidaskClub cut Cellectis from a sell rating to a strong sell rating in a research note on Friday, September 7th. Zacks Investment Research raised Cellectis from a hold rating to a buy rating and set a $25.00 price objective on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of $48.00.
Shares of NASDAQ:CLLS opened at $22.00 on Friday. Cellectis has a 52-week low of $21.29 and a 52-week high of $38.85. The company has a market capitalization of $915.32 million, a P/E ratio of -7.91 and a beta of 1.76.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Read More: Depreciation
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.